Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Inclusion Criteria: * Confirmed HCC based on histopathological findings from tumor tissue or radiologically findings * No prior systemic therapy for HCC * Barcelona Clinic Liver Cancer (BCLC) stage B (not eligible for locoregional therapy) or stage C * Child-Pugh Score class A or B * ECOG performance status (PS) of 0-2 at enrollment (Child-Pugh Score class A and ECOG PS of 0-1 will be enrolled in cohort 1 and Child-Pugh Score class B or ECOG PS of 2 will be enrolled in cohort 2) * At least 1 measurable lesion per RECSIT 1.1 guidelines Exclusion Criteria: * Hepatic encephalopathy within past 12 months or requirement for medication to prevent or control encephalopathy * Clinically meaningful ascites * Main portal vein tumor thrombosis * Active or prior documented GI bleeding (eg, esophageal varices or ulcer bleeding) within 6 months * HBV and HVC co-infection, or HBV and Hep D co-infection